CimetrA®

Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical and Clinical program, meeting FDA guidelines, to date: • Demonstrated suppression of cytokine storm in Phase II Clinical Trials1 • Demonstrated significant reduction in C-reactive protein (CRP), a major inflammatory marker2 . • The biological markers in the blood tests further proved a reduction of inflammation, enterohepatic involvement, and liver reactant proteins1 . • Effective blocking of the IL-32mRNA expression1 , the pro-inflammatory cytokine related to Autoimmune diseases, lupus, rheumatoid arthritis, inflammatory bowel disease, asthma, and chronic obstructive pulmonary disease1 • Preclinical studies in rodents (rats, mice) and non-rodent (swine) confirm the safety profile, with no formulation-related toxicity detected3.